Press Review

Can DalCor Pharma Succeed Where Others Have Failed?

June 1, 2017

DalCor Pharmaceuticals today announced it has exceeded its enrollment schedule with 50 percent of patients randomized in its Phase 3 “dalGenE” clinical trial. More than 2,500 out of 5,000 expected patients with acute coronary syndrome (ACS) and the AA genotype at variant rs1967309 in the ADCY9 gene have entered into…

READ MORE ›

Genetically Targeting Dalcetrapib to the Right Patients

April 28, 2017

DalCor Pharmaceuticals seeks to deliver superior clinical cardiovascular outcomes by integrating clinical and genetic insights to target treatments to patients who will derive clinical benefits. The company’s first development program, dalcetrapib, is intended to reduce cardiovascular events in a specific genetic subset of patients.

READ MORE ›

DalCor CVOT Moves Along; Seek Dalcetrapib CETP Win with Roche Diagnostic Test

March 8, 2017

With enrollment about six months ahead of schedule, precision medicine specialist Dalcor Pharmaceuticals Inc. has randomized more than 1,000 patients of the expected 5,000 for the phase III dal-Gene trial, a cardiovascular outcomes (CVOT) study of dalcetrapib in patients with acute coronary syndrome (ACS) who have the AA genotype in…

READ MORE ›

With $150M in the Bank, DalCor Seeks Phase III Success with Dalcetrapib

April 20, 2016

Seeking to succeed where big pharma failed, start-up Dalcor Pharma UK Ltd. completed a $100 million series B round to put an exclamation point on the $50 million series A the company closed late in 2015. The company was launched a year ago by Sanderling Ventures LLC with a new…

READ MORE ›

Startup Aims to Revive Failed Drug

April 20, 2016

A London-based startup is making a risky bet that a surprising genetic variation will enable it to find success in one of the pharmaceutical industry’s biggest flops. DalCor Pharmaceuticals said it has raised $150 million in venture financing to mount a 5,000-patient trial of a cholesterol drug called dalcetrapib that…

READ MORE ›